Mamta K. Jain
Expertise in
25
conditions

Dr. Mamta K. Jain

Internal Medicine
3115 College Park Dr, Ste 112, 
The Woodlands, TX 
Accepting New Patients
28 Years of Experience
Expertise in
25
conditions
3115 College Park Dr, Ste 112, 
The Woodlands, TX 

Overview

Mamta Jain is a primary care provider, practicing in Internal Medicine in The Woodlands, Texas. She has been practicing medicine for over 28 years.

Dr. Jain is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Hepatitis, HIV/AIDS, Hepatitis C, Hepatitis B, and Endoscopy.

She is actively involved in clinical research, co-authoring 145 peer reviewed articles and participating in 6 clinical trials. Dr. Jain is currently accepting new patients.

Specialties

Internal Medicine

Licenses

Internal Medicine in TX

Fellowships

Albert Einstein College of Medicine - Graduate Medical Education 2008

Hospital Affiliations

Chi St Lukes Lakeside Hospital
Memorial Hermann Hospital System
Tops Surgical Specialty Hospital
Houston Methodist The Woodlands Hospital
St Luke's The Woodlands Hospital

Languages Spoken

English
Gujarati 
Hindi

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medica
  • EPO
  • HMO
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
SelectHealth
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

3115 College Park Dr, Ste 112, The Woodlands, TX 77384

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
An International Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the Treatment of Adult Outpatients in Early Stages of COVID-19
Enrollment Status: Terminated
Publish Date: August 13, 2026
Intervention Type: Biological, Other
Study Drug: Hyperimmune Immunoglobulin to SARS-CoV-2 (hIVIG)
Study Phase: Phase 3
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
RESOLUTION: A Double-blind, Randomized, Placebo-controlled, Phase II/III Study of the Efficacy and Safety of LAU-7b in the Treatment of Adult Hospitalized Patients With COVID-19 Disease
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Drug
Study Drug: Fenretinide
Study Phase: Phase 2/Phase 3
HBV-HIV Coinfection Research Network
HBV-HIV Coinfection Research Network
Enrollment Status: Completed
Publish Date: May 16, 2023
Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations
Human Immunodeficiency Virus Acquired Lipodystrophy (HAL) Classification, Measurement, & Fat Response to a Thiazolidinedione (TZD) Challenge in Differing Adult Phenotypic Presentations
Enrollment Status: Completed
Publish Date: October 08, 2019
Intervention Type: Other, Drug
Study Phase: Not Applicable
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
A Prospective, Randomized, Placebo-controlled, Double-blind Clinical Trial to Evaluate Whether EGRIFTA® (Tesamorelin for Injection), 2 mg Once Daily SC, Increases the Risk of Development or Progression of Diabetic Retinopathy When Administered to HIV-infected Subjects With Abdominal Lipohypertrophy and Concomitant Diabetes
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
Study Phase: Phase 4
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects With HIV-associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for Injection) to a Similar Group of Subjects Not Exposed to EGRIFTA®
Enrollment Status: Terminated
Publish Date: September 11, 2018
Intervention Type: Drug
View 5 Less Clinical Trials

145 Total Publications

Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.
Projected Increase in HIV Incidence in 11 States if Ryan White Ends: A Simulation Study.
Journal: American journal of public health
Published: April 08, 2026
Similar Doctors
Expertise in
16
conditions
Dr. Risheng X. Xu
Internal Medicine
Expertise in
16
conditions
Dr. Risheng X. Xu
Internal Medicine

St. Luke's Health - The Vintage Hospital

20171 Chasewood Park Dr, 
Houston, TX 
 (16.2 miles away)
832-534-5400
Languages Spoken:
English
See accepted insurances

Risheng Xu is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Xu is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Trigeminal Neuralgia, Subdural Hematoma, Moyamoya Disease, Microvascular Decompression, and Rhizotomy.

Expertise in
26
conditions
Dr. Maro N. Ohanian
Internal Medicine
Expertise in
26
conditions
Dr. Maro N. Ohanian
Internal Medicine

University Of Texas MD Anderson Cancer Center

1515 Holcombe Blvd Unit 428, 
Houston, TX 
 (34.7 miles away)
713-792-8760
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Maro Ohanian is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Ohanian is highly rated in 26 conditions, according to our data. Her clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine
Expertise in
17
conditions
Dr. Preetesh M. Jain
Internal Medicine

UT MD Anderson Cancer Center

1515 Holcombe Blvd, 
Houston, TX 
 (34.7 miles away)
713-792-1101
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Preetesh Jain is a primary care provider, practicing in Internal Medicine in Houston, Texas. Dr. Jain is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Mamta K. Jain

How do I make an appointment with Dr. Mamta K. Jain?

You can book an appointment with Dr. Mamta K. Jain by calling their office at 281-836-3627. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Mamta K. Jain a top-rated expert for Hepatitis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Mamta K. Jain is classified as an Distinguished expert for Hepatitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Mamta K. Jain specialize in?

While Dr. Mamta K. Jain is a Internal Medicine, they have specific expertise in Hepatitis, HIV/AIDS, and Hepatitis C. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Mamta K. Jain participate in research or clinical trials?

Yes. Dr. Mamta K. Jain has published 145 articles and abstracts on conditions like Hepatitis. You can view a list of Dr. Mamta K. Jain's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Mamta K. Jain accept my insurance?

Dr. Mamta K. Jain accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 281-836-3627 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
    View All 21 Advanced Conditions
    View All 81 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile